Work

Abstract PS1-09-02: Intracranial activity of datopotamab deruxtecan (Dato-DXd) for patients with HER2-negative breast cancer and leptomeningeal disease (LMD): Results from Cohort C of the DATO-BASE phase 2 trial

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps1-09-02

Institutions: Dana-Farber Cancer Institute, Yale University, Duke Medical Center, Duke Cancer Institute, Baptist Health South Florida, Brigham and Women's Hospital

Language: English

Topic: Brain Metastases and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129618420

Cites:

Cited by: 1

Related to: